Viomi Technology Co (NASDAQ:VIOT) reported $138.00 million in sales this quarter. This is a 46.29 percent decrease over sales of $256.93 million the same period last year.
Aerovate Therapeutics To Present Patient Baseline Characteristics Of The Phase 2b Portion Of The Phase 2b/Phase 3 IMPAHCT Trial At The American Thoracic Society 2024 International Conference
Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster